Oncocyte (NASDAQ:IMDX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Oncocyte (NASDAQ:IMDX) to a hold rating in a research report sent to investors on Saturday morning.

Oncocyte Trading Up 1.2%

Shares of IMDX opened at $6.11 on Friday. The firm has a market capitalization of $175.11 million, a P/E ratio of -2.16 and a beta of 1.33. Oncocyte has a fifty-two week low of $1.92 and a fifty-two week high of $8.51.

Oncocyte Company Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.